Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Cash from Operations (2020 - 2025)

Gain Therapeutics (GANX) has 6 years of Cash from Operations data on record, last reported at 4926436.0 in Q3 2025.

  • For Q3 2025, Cash from Operations rose 18.92% year-over-year to 4926436.0; the TTM value through Sep 2025 reached 17301581.0, up 17.92%, while the annual FY2024 figure was 18873827.0, 0.04% changed from the prior year.
  • Cash from Operations reached 4926436.0 in Q3 2025 per GANX's latest filing, up from 5098982.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 2192338.0 in Q3 2021 and bottomed at 6076205.0 in Q3 2024.
  • Average Cash from Operations over 5 years is 4139181.79, with a median of 3966715.0 recorded in 2023.
  • Peak YoY movement for Cash from Operations: plummeted 658.41% in 2021, then soared 38.97% in 2024.
  • A 5-year view of Cash from Operations shows it stood at 4146365.0 in 2021, then grew by 5.83% to 3904613.0 in 2022, then crashed by 44.97% to 5660379.0 in 2023, then skyrocketed by 38.97% to 3454636.0 in 2024, then crashed by 42.6% to 4926436.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 4926436.0 in Q3 2025, 5098982.0 in Q2 2025, and 3821527.0 in Q1 2025.